<DOC>
	<DOCNO>NCT02873156</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacodynamics ( PD ) pharmacokinetics ( PK ) multiple ascend oral dos E2027 healthy participant .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics , Pharmacodynamics E2027 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Nonsmoking , male female , age ≥50 year ≤85 year old time inform consent 2 . Body mass index ( BMI ) ≥18 ≤32 kilogram per square meter ( kg/m2 ) Screening Exclusion Criteria 1 . Clinically significant illness require medical treatment within 8 week clinically significant infection require medical treatment within 4 week dose 2 . Females breastfeed pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ beta ( ß ) hCG ] ( human chorionic gonadotropin [ hCG ] ) test minimum sensitivity 25 International Unit per Liter ( IU/L ) equivalent unit ßhCG [ hCG ] ) . A negative urine pregnancy test require administration 1st dose per cohort . 3 . Females childbearing potential : Had unprotected sexual intercourse within 30 day study entry agree use highly effective method contraception ( eg , total abstinence , intrauterine device , double barrier method [ condom plus diaphragm spermicide ] vasectomize partner confirm azoospermia hormonal contraceptive permit ) throughout entire study period 28 day study drug discontinuation Are currently abstinent , agree use double barrier method ( describe ) refrain sexual activity study period 28 day study drug discontinuation NOTE : All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( ie , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 4 . Males successful vasectomy ( confirm azoospermia ) female partner meet criterion ( ie , childbearing potential practicing highly effective contraception throughout study period 28 day study drug discontinuation ) . No sperm donation allow study period 28 day study drug discontinuation 5 . Medical condition adequately stably control stable dos medication , clinical opinion Principal Investigator ( PI ) , may interfere study procedure participant safety within 4 week dose ( eg , psychiatric disorder disorder gastrointestinal tract , liver , kidney , respiratory system , endocrine system , hematological system , neurological system , cardiovascular system , participant congenital abnormality metabolism ) . Participants follow stable medical condition , adequately control stable dos concomitant medication , need exclude opinion PI , condition compromise participant safety study procedure : hypertension without cerebrovascular cardiovascular complication , control 1 antihypertensive drug hyperlipidemia without cerebrovascular cardiovascular complication , control diet monotherapy medication mild , localize disease skin , respiratory tract require systemic medication treatment without systemic complication mild , localized disease eye symptomatic require systemic medication treatment without systemic complication osteoarthritis require opioids treatment pain 6 . History cerebrovascular disease ( include transient ischemic attack stroke ) 7 . Any history abdominal surgery may affect pharmacokinetic ( PK ) profile E2027 ( eg , hepatectomy , nephrectomy , digestive organ resection ) Screening Baseline 8 . Any clinically abnormal symptom organ impairment find medical history , physical examination , vital sign , electrocardiogram ( ECG ) finding , laboratory test result require medical treatment Screening Baseline 9 . A prolonged QT/QTc interval ( QTc &gt; 450 millisecond [ m ] ) demonstrate ECG Screening Baseline ( base average triplicate ECGs ) . A history risk factor torsade de pointes ( eg , heart failure , hypokalemia , family history long QT Syndrome ) use concomitant medication prolong QT/QTc interval 10 . Left bundle branch block Screening Baseline 11 . Persistent systolic blood pressure ( BP ) &gt; 160 millimeter mercury ( mm Hg ) diastolic BP &gt; 100 mm Hg Screening Baseline ( base BP measure least 3 occasion 2 week ) 12 . Persistent heart rate ( HR ) less 50 beats/minute ( min ) 90 beats/min Screening Baseline ( base HR measure least 3 occasion 2 week ) 13 . History myocardial infarction , ischemic heart disease cardiac failure 14 . History clinically significant arrhythmia uncontrolled arrhythmia 15 . Known history clinically significant drug allergy Screening Baseline 16 . Known history food allergy presently experience significant seasonal perennial allergy Screening Baseline 17 . Known human immunodeficiency virus ( HIV ) positive Screening 18 . Active viral hepatitis ( A , B , C ) demonstrate positive serology Screening 19 . History drug alcohol dependency abuse within 2 year Screening , positive urine drug alcohol test Screening Baseline ( participant whose positive urine drug test consider investigator sponsor medical monitor due permit concomitant medication need exclude ) 20 . Participants smoke used tobacco nicotinecontaining product within 4 week dose 21 . A Columbia Suicide Severity Rating Scale ( CSSRS ) suicidal ideation score 4 5 Screening Baseline period within 6 month Screening Baseline lifetime suicidal behavior 22 . Currently enrol another clinical study use investigational drug device within 30 day ( 5 halflives , whichever long ) precede inform consent 23 . Engagement strenuous exercise within 2 week checkin ( eg , marathon runner , weight lifter ) 24 . Any contraindication cerebrospinal fluid ( CSF ) sample lumbar puncture ( LP ) 25 . Participants platelet count &lt; 60,000 , international normalize ratio ( INR ) &gt; 1.2 , partial thromboplastin time ( PTT ) &gt; upper limit normal ( ULN ) Screening 26 . Intake caffeinated beverage caffeinated food within 72 hour dose 27 . Intake nutritional supplement , juice , herbal preparation food beverage may affect various drug metabolize enzyme transporter ( eg , alcohol , grapefruit , grapefruit juice , grapefruitcontaining beverage , apple orange juice , vegetables mustard green family [ eg , kale , broccoli , watercress , collard green , kohlrabi , brussel sprout , mustard ] , charbroiled meat ) within 1 week dose 28 . Intake herbal preparation contain St. John 's Wort within 4 week dose . 29 . Intake overthecounter ( OTC ) medication within 14 day ( 5 halflives , whichever long ) dose unless principal investigator sponsor medical monitor consider compromise participant safety study assessment 30 . Participants take prohibited medication list Concomitant Drug/Therapy section within 14 day dose</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>E2027</keyword>
	<keyword>Healthy participant</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>